drugset / Trial / NCT03997760
A Study of SHP655 (rADAMTS13) in Sickle Cell Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
TAK-755 (previously known as SHP655) is a medicine used to treat sickle cell disease (SCD). The main aim of the study is to measure the safety and tolerability of TAK-755 in SCD participants. Study participants will receive TAK-755 or placebo on Day 1. Their SCD will be treated by their doctor according to their doctor's usual clinical practice. During the study, participants will be asked to follow-up on 13 days following SHP655 or placebo administration for safety assessment. Maximum duration of participation is expected to be about 2 months.
Timeline
- Start
- 2019-10-21
- Primary completion
- 2022-10-26
- Completion
- 2022-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAK-755 | Protein / enzyme biologic | 40 iu/kg | Intravenous |
| Subject | TAK-755 | Protein / enzyme biologic | 80 iu/kg | Intravenous |
| Subject | TAK-755 | Protein / enzyme biologic | 160 iu/kg | Intravenous |